Farheen Mir

512 total citations
13 papers, 167 citations indexed

About

Farheen Mir is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Farheen Mir has authored 13 papers receiving a total of 167 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 5 papers in Genetics and 5 papers in Oncology. Recurrent topics in Farheen Mir's work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (4 papers). Farheen Mir is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (4 papers). Farheen Mir collaborates with scholars based in United Kingdom, Switzerland and Australia. Farheen Mir's co-authors include Tina Nielsen, Gul Bano, Wolfgang Hiddemann, Robert Marcus, Catherine Egan, Michael Herold, Sally F. Barrington, John F. Seymour, Deniz Şahin and Michel Meignan and has published in prestigious journals such as Blood, Journal of Nuclear Medicine and American Journal of Hematology.

In The Last Decade

Farheen Mir

13 papers receiving 165 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Farheen Mir United Kingdom 6 109 74 46 39 25 13 167
Jesse Shustik Canada 5 114 1.0× 78 1.1× 26 0.6× 8 0.2× 50 2.0× 11 142
Harald Zeuner Switzerland 6 62 0.6× 99 1.3× 21 0.5× 10 0.3× 23 0.9× 11 143
Sandra Lockmer Sweden 5 190 1.7× 154 2.1× 18 0.4× 46 1.2× 80 3.2× 12 209
Allison Barraclough Australia 8 106 1.0× 87 1.2× 19 0.4× 4 0.1× 30 1.2× 29 152
Eva Díaz Spain 6 53 0.5× 53 0.7× 57 1.2× 19 0.5× 13 0.5× 15 143
Barbara Mantoan Italy 7 106 1.0× 71 1.0× 28 0.6× 6 0.2× 53 2.1× 13 155
Muhammed B. Sabdia Australia 6 66 0.6× 96 1.3× 36 0.8× 5 0.1× 11 0.4× 17 144
Divya Kriplani United Kingdom 5 28 0.3× 74 1.0× 96 2.1× 37 0.9× 6 0.2× 8 155
David Šálek Czechia 8 130 1.2× 102 1.4× 30 0.7× 3 0.1× 44 1.8× 23 156
Jakob Jóhannsson Iceland 4 48 0.4× 39 0.5× 31 0.7× 7 0.2× 6 0.2× 7 108

Countries citing papers authored by Farheen Mir

Since Specialization
Citations

This map shows the geographic impact of Farheen Mir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farheen Mir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farheen Mir more than expected).

Fields of papers citing papers by Farheen Mir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farheen Mir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farheen Mir. The network helps show where Farheen Mir may publish in the future.

Co-authorship network of co-authors of Farheen Mir

This figure shows the co-authorship network connecting the top 25 collaborators of Farheen Mir. A scholar is included among the top collaborators of Farheen Mir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farheen Mir. Farheen Mir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Casulo, Carla, Michael Herold, Wolfgang Hiddemann, et al.. (2022). Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. Clinical Lymphoma Myeloma & Leukemia. 23(1). 40–48. 14 indexed citations
2.
Barrington, Sally F., Farheen Mir, Tarec Christoffer El‐Galaly, et al.. (2021). Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study. Journal of Nuclear Medicine. 63(8). 1149–1154. 3 indexed citations
3.
Bolen, Christopher R., Federico Mattiello, Michael Herold, et al.. (2021). Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. Blood. 137(19). 2704–2707. 17 indexed citations
4.
Mir, Farheen, Sally F. Barrington, Helen Brown, et al.. (2020). Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood. 135(15). 1214–1218. 31 indexed citations
5.
6.
Bolen, Christopher R., Wolfgang Hiddemann, Robert Marcus, et al.. (2019). TREATMENT‐DEPENDENCE OF HIGH‐RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA. Hematological Oncology. 37(S2). 193–194. 5 indexed citations
7.
Casulo, Carla, Michael Herold, Wolfgang Hiddemann, et al.. (2019). Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study. Blood. 134(Supplement_1). 5268–5268. 2 indexed citations
8.
Bolen, Christopher R., Wolfgang Hiddemann, Robert Marcus, et al.. (2019). S100 TREATMENT‐DEPENDENCE OF HIGH‐RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA. HemaSphere. 3(S1). 1–1. 1 indexed citations
9.
10.
Mir, Farheen, Sally F. Barrington, Michel Meignan, et al.. (2018). Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study. Blood. 132(Supplement 1). 4160–4160. 4 indexed citations
11.
12.
Mir, Farheen, et al.. (2014). Maternally inherited diabetes and deafness (MIDD): Diagnosis and management. Journal of Diabetes and its Complications. 28(4). 542–546. 49 indexed citations
13.
Bano, Gul, et al.. (2012). A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1. International Journal of Endocrinology and Metabolism. 11(1). 52–6. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jesse Shustik Breakdown of academic impact, for papers by Harald Zeuner Breakdown of academic impact, for papers by Sandra Lockmer Breakdown of academic impact, for papers by Allison Barraclough Breakdown of academic impact, for papers by Eva Díaz Breakdown of academic impact, for papers by Barbara Mantoan Breakdown of academic impact, for papers by Muhammed B. Sabdia Breakdown of academic impact, for papers by Divya Kriplani Breakdown of academic impact, for papers by David Šálek Breakdown of academic impact, for papers by Jakob Jóhannsson
Rankless by CCL
2026